tiprankstipranks
Advertisement
Advertisement
Tempus AI: Buy Rating Reiterated as Analyst Maintains $75 Price Target on Durable Growth and Improving Financial Profile
PremiumRatingsTempus AI: Buy Rating Reiterated as Analyst Maintains $75 Price Target on Durable Growth and Improving Financial Profile
13d ago
Short Report: Tempus AI short interest at record high
Premium
The Fly
Short Report: Tempus AI short interest at record high
13d ago
Tempus AI announces launch of PRECISION Challenge for oncology breakthroughs
Premium
The Fly
Tempus AI announces launch of PRECISION Challenge for oncology breakthroughs
13d ago
Tempus AI announces initial results from Multimodal Foundation Model efforts
PremiumThe FlyTempus AI announces initial results from Multimodal Foundation Model efforts
15d ago
Tempus AI receives FDA approval for tumor-only xT CDx
Premium
The Fly
Tempus AI receives FDA approval for tumor-only xT CDx
15d ago
Tempus AI announces expansion of indications to Next platform
Premium
The Fly
Tempus AI announces expansion of indications to Next platform
16d ago
Tempus AI Earnings Call Highlights Data-Driven Growth
PremiumCompany AnnouncementsTempus AI Earnings Call Highlights Data-Driven Growth
25d ago
Tempus AI announces strategic collaboration with Bristol Myers
Premium
The Fly
Tempus AI announces strategic collaboration with Bristol Myers
1M ago
Tempus AI Completes Convertible Notes Offering, Retires Secured Debt
Premium
Company Announcements
Tempus AI Completes Convertible Notes Offering, Retires Secured Debt
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100